目的：对急性心肌梗死(AMI)患者应用氯吡格雷联合辛伐他汀治疗对再发的预防效果评价进行分析。方法资料随机选自2011年4月-2013年4月该该院诊治的急性心肌梗死患者120例，将患者分为两组，每组60例，两组均予以溶栓治疗，对照组在溶栓基础上予以常规治疗，研究组在溶栓基础上予以氯吡格雷联合辛伐他汀治疗，并分析两组患者的病死率和再梗死率情况及不良反应情况。结果比较两组患者12个月后的病死率和再梗死率情况，研究组患者的病死率为3.3%，再梗死率为5.0%，对照组患者的病死率为11.6%，再梗死率为13.3%，研究组明显优于对照组；比较两组患者出现的不良反应情况，研究组的发生率为18.3%，对照组的发生率为35.0%，研究组明显优于对照组，比较差异有统计学上的意义（P＜0.05）。结论通过应用氯吡格雷联合辛伐他汀来治疗急性心肌梗死患者，能够减少心肌梗死的复发率，提升临床的治疗的效果。%Objective To evaluate the effect of clopidogrel and simvastatin on acute myocardial infarction (AMI) patients for pre-venting the recurrence of the disease. Methods The data of 120 cases of patients with acute myocardial infarction admitted in our hospital from April, 2011 to April, 2013 were selected. The patients were divided into two groups, 60 cases in each group. On the basis of thrombolytic therapy, the control group was given conventional treatment, and the study group was given clopidogrel com-bined with simvastatin for treatment. The mortality and reinfarction rate and adverse reactions of two groups were analyzed. Results The mortality and reinfarction rate of two groups were compared after 12 months, the mortality and reinfarction rate of the study group was 3.3%, 5.0%separately, while that of the control group was 11.6%, 13.3%, respectively, the effect of the study group was much better than that of the control group. The incidence of adverse reactions of the study group was 18.3%, which was signifi-cantly lower than 35.0%of the control group, the difference was statistically significant (P<0.05). Conclusion For the treatment of patients with acute myocardial infarction, clopidogrel and simvastatin can reduce the recurrence rate of myocardial infarction and improve the clinical effect.
展开▼
